ETCTN Trials by Disease/Treatment Area: Leukemia

**Leukemia**

- **R/R CD19+ precursor B-lymphoblastic leukemia**
- **CD3+ acute lymphoma, or poor-risk chronic subtypes of adult T-cell lymphoma/leukemia**
- **R/R AML, myelodysplastic syndrome, or chronic myelomonocytic leukemia**
- **AML with wild-type p53 (R/R or front line)**
- **Mutated AML**
- **AML (front line therapy)**
- **Hematologic malignancy**
- **Hematologic malignancy, not otherwise stated**

**Lymphocytic**

- **10030**: A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitors (PD-1 [Nivolumab] or Both PD-1 [Nivolumab] and CTLA-4 [Ipilimumab]) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

**Myelogenous**

- **10335**: A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia/Lymphoma (ATLL)
- **10036**: A Phase 1 Study of Ipilimumab in Combination with Daclizumab in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
- **10246**: A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- **10075**: A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia

- **10008**: A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitors (PD-1 [Nivolumab]) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

**Hematologic malignancy**

- **10014**: A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

**Hematologic malignancy, not otherwise stated**

- **10334**: A Phase 2 Study of Venetoclax, Azacitadine, and Pembrolizumab Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy

**NOTE**: *No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 15, 2021*